Par Drugs & Chemicals Ltd
Incorporated in 1982, Par Drugs & Chemicals Ltd manufactures APIs and Fine Chemicals[1]
- Market Cap ₹ 384 Cr.
- Current Price ₹ 312
- High / Low ₹ 325 / 190
- Stock P/E 21.0
- Book Value ₹ 78.6
- Dividend Yield 0.00 %
- ROCE 25.0 %
- ROE 18.5 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Debtor days have improved from 68.9 to 52.3 days.
- Company's working capital requirements have reduced from 50.4 days to 40.2 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
19 | 27 | 33 | 33 | 49 | 42 | 46 | 56 | 61 | 75 | 96 | 96 | 104 | |
15 | 20 | 26 | 26 | 40 | 34 | 38 | 46 | 45 | 59 | 78 | 73 | 77 | |
Operating Profit | 3 | 7 | 7 | 7 | 8 | 8 | 8 | 9 | 16 | 16 | 18 | 23 | 27 |
OPM % | 18% | 27% | 22% | 22% | 17% | 19% | 18% | 17% | 26% | 22% | 19% | 24% | 26% |
-0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | |
Interest | 1 | 4 | 4 | 4 | 2 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 |
Depreciation | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 |
Profit before tax | 2 | 1 | 1 | 1 | 3 | 3 | 3 | 6 | 15 | 13 | 15 | 20 | 25 |
Tax % | 34% | 40% | 27% | 58% | 42% | 42% | 24% | 21% | 21% | 27% | 25% | 26% | |
1 | 1 | 1 | 0 | 2 | 2 | 3 | 5 | 12 | 9 | 11 | 14 | 18 | |
EPS in Rs | 2.07 | 1.33 | 1.65 | 0.78 | 3.43 | 2.78 | 2.79 | 3.87 | 9.44 | 7.49 | 9.21 | 11.78 | 14.85 |
Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | 32% | -0% | -0% | -0% | -0% |
Compounded Sales Growth | |
---|---|
10 Years: | 13% |
5 Years: | 16% |
3 Years: | 16% |
TTM: | 8% |
Compounded Profit Growth | |
---|---|
10 Years: | 35% |
5 Years: | 42% |
3 Years: | 13% |
TTM: | 44% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 70% |
3 Years: | 8% |
1 Year: | 44% |
Return on Equity | |
---|---|
10 Years: | 16% |
5 Years: | 18% |
3 Years: | 17% |
Last Year: | 18% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 6 | 6 | 12 | 12 | 12 | 12 |
Reserves | 6 | 8 | 9 | 9 | 11 | 12 | 25 | 34 | 46 | 48 | 59 | 73 | 84 |
16 | 44 | 38 | 36 | 31 | 29 | 12 | 6 | 8 | -0 | -0 | -0 | -0 | |
4 | 7 | 9 | 10 | 12 | 10 | 11 | 13 | 16 | 19 | 18 | 16 | 19 | |
Total Liabilities | 29 | 61 | 59 | 58 | 56 | 54 | 51 | 60 | 76 | 79 | 89 | 102 | 116 |
14 | 47 | 45 | 43 | 42 | 39 | 36 | 34 | 30 | 34 | 38 | 41 | 40 | |
CWIP | 6 | -0 | -0 | -0 | -0 | -0 | -0 | 1 | 5 | 0 | 0 | 0 | -0 |
Investments | -0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26 |
9 | 14 | 13 | 15 | 14 | 15 | 15 | 25 | 42 | 44 | 50 | 60 | 50 | |
Total Assets | 29 | 61 | 59 | 58 | 56 | 54 | 51 | 60 | 76 | 79 | 89 | 102 | 116 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 5 | 9 | 7 | 9 | 4 | 2 | 8 | 12 | 8 | 13 | 20 | |
-7 | -6 | -0 | -0 | -2 | -1 | -0 | -1 | 0 | -3 | -7 | -6 | |
6 | 2 | -9 | -5 | -8 | -4 | -2 | 1 | 2 | -10 | -0 | -0 | |
Net Cash Flow | 0 | 1 | -1 | 1 | -1 | 0 | -0 | 7 | 14 | -5 | 6 | 14 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 67 | 104 | 83 | 81 | 61 | 75 | 67 | 81 | 75 | 90 | 65 | 52 |
Inventory Days | 129 | 111 | 158 | 69 | 83 | 81 | 45 | 50 | 60 | 49 | 45 | |
Days Payable | 171 | 184 | 183 | 135 | 107 | 94 | 96 | 112 | 135 | 73 | 58 | |
Cash Conversion Cycle | 67 | 62 | 10 | 57 | -5 | 51 | 55 | 30 | 13 | 14 | 40 | 40 |
Working Capital Days | 114 | 102 | 61 | 66 | -4 | 18 | 47 | 39 | 44 | 61 | 50 | 40 |
ROCE % | 12% | 10% | 9% | 12% | 11% | 12% | 16% | 25% | 22% | 23% | 25% |
Documents
Announcements
-
Copy of Newspaper Publication
23 October 2024 - Par Drugs And Chemicals Limited has informed about Copy of Newspaper Publication
-
Outcome of Board Meeting
22 October 2024 - Par Drugs And Chemicals Limited has informed regarding Board meeting held on October 22, 2024.
-
Updates
22 October 2024 - Par Drugs And Chemicals Limited has informed regarding 'Outcome of Board Meeting 22.10.2024'.
-
Financial Result Updates
22 October 2024 - Par Drugs And Chemicals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2024.
-
Outcome of Board Meeting
22 October 2024 - Par Drugs And Chemicals Limited has informed regarding Outcome of Board Meeting held on October 22, 2024.
Annual reports
Concalls
-
Jun 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
Mar 2023TranscriptNotesPPT
-
Mar 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Dec 2021TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Sep 2019TranscriptNotesPPT
Business Overview:[1]
PACL manufactures Active Pharma Ingredients for domestic and exports markets, they have a portfolio of 15 APIs and 10 Fine Chemicals. It produces the entire range of products in the Antacid Molecules segment